What does the TOURMALINE-MM2 study tell us about the use of ixazomib in multiple myeloma?
COMy 2016: Highlights from Day 1
Arnon Nagler et al.
What is the rationale for novel combination therapies?
Niels van de Donk
Myeloma 2016: Panel discussion on the application of genomics studies
Leif Bergsagel et al.
History of approvals for proteasome inhibitors bortezomib, carfilzomib and ixazomib